Plain-English translation of NCT07769827 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment approach for advanced liver cancer in people with hepatitis B. The study combines pegylated interferon alpha-2b with two other types of cancer-fighting therapy (targeted therapy and immunotherapy drugs called PD-1 inhibitors). Researchers want to see if this three-part combination can slow or stop cancer growth in people whose cancer cannot be surgically removed.
Advanced liver cancer that cannot be surgically removed is very difficult to treat, and people with hepatitis B have limited options. This medication and similar treatments have shown promise in other cancers, but doctors want to test whether combining them together works better for this specific type of advanced liver cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the medication and immunotherapy treatments on a schedule, with each 6-week period counted as one treatment cycle. You would continue treatment as long as it is working and you are tolerating it well, and you would come in for regular visits to have blood tests, imaging scans, and check-ups. If your cancer gets worse or you develop serious side effects, your doctor would discuss stopping the treatment with you. Follow-up visits would continue according to the study protocol after treatment ends.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China